Trial Profile
A Multi-centre, Randomised, Parallel Group, Open-label, Phase II, Single-stage Selection Trial of Liposomal Irinotecan (Nal-IRI) and 5-fluorouracil (5-FU)/Folinic Acid or Docetaxel as Second-line Therapy in Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma (NEC))
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- Acronyms NET-02
- 08 Jun 2023 Planned End Date changed from 25 Nov 2022 to 1 Dec 2023.
- 08 Jun 2023 Planned primary completion date changed from 25 Nov 2022 to 1 Dec 2023.
- 21 Jan 2023 NET-02 final results presented at the 2023 Gastrointestinal Cancers Symposium